NEW YORK, September 5, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
--
Medtronic, Inc. Research Reports
On September 2, 2014, Medtronic, Inc. (Medtronic) announced its participation at the upcoming Morgan Stanley Global Healthcare Conference on September 8, 2014, in New York. The Company informed that its Executive Vice President and CFO, Gary Ellis, will give a presentation on Medtronic at 3:25 p.m. EDT or 2:25 p.m. CDT. Further, a live audio webcast of the presentation will be available on the Company's official website under investors section. The full research reports on Medtronic are available to download free of charge at:
http://www.analystsreview.com/Sep-05-2014/MDT/report.pdf
--
Humana Inc. Research Reports
On August 27, 2014, Humana Inc. (Humana) announced that the Company's Board of Directors has declared a $0.28 per share cash dividend, payable on October 31, 2014 to stockholders of record as of the close of business on September 30, 2014. The recently announced dividend is unchanged from the dividend announced in the previous quarter. The full research reports on Humana are available to download free of charge at:
http://www.analystsreview.com/Sep-05-2014/HUM/report.pdf
--
Shire Plc Research Reports
On September 1, 2014, Shire Plc (Shire) announced its total voting rights in accordance with the Financial Conduct Authority's (FCA) Disclosure and Transparency Rule 5.6.1R. The Company informed that at the close of business on August 31, 2014, its issued ordinary share capital comprised c.589.56 million ordinary shares of 5 pence each with voting rights. Further, the Company holds 9.02 million ordinary shares in treasury. Shire stated that the number of voting rights in the Company is c.589.56 million, and this figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. The full research reports on Shire are available to download free of charge at:
http://www.analystsreview.com/Sep-05-2014/SHPG/report.pdf
--
Biogen Idec Inc. Research Reports
On September 2, 2014, Biogen Idec Inc. (Biogen) announced that the Company will present at the upcoming Morgan Stanley Global Healthcare Conference 2014 on September 8, 2014. The Company informed that the live webcast of the conference will be available from 2:00 p.m. ET on the same day on its official website under investors section. The full research reports on Biogen are available to download free of charge at:
http://www.analystsreview.com/Sep-05-2014/BIIB/report.pdf
--
Covidien plc Research Reports
On August 28, 2014, Covidien plc (Covidien) announced that the Company has acquired Sapheon, Inc., (Sapheon), a privately-held developer of venous disease treatments, without disclosing the financial terms of the transaction. The Company informed that Sapheon is engaged in the manufacturing and development of the VenaSeal® system, which uses a specially formulated medical adhesive to close the great saphenous vein in patients with varicose veins and chronic venous insufficiency (CVI). The Company stated that the transaction will be slightly dilutive to adjusted earnings, but will not have a material impact on the Company's results. Covidien plans to report Sapheon business as part of its Peripheral Vascular product line in the Medical Devices segment. Brian Verrier, President, Peripheral Vascular, Covidien, said, "Sapheon will significantly enhance Covidien's global Peripheral Vascular business by providing additional treatment options for physicians and their patients who suffer from CVI. Sapheon's technology is complementary to our current portfolio, and this acquisition further demonstrates Covidien's leadership in the CVI space." The full research reports on Covidien are available to download free of charge at:
http://www.analystsreview.com/Sep-05-2014/COV/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
